Physician profile

Armin Krvavac

Critical Care Medicine (Internal Medicine) · Saint Louis, MO

NPI 1134482490

$793.41

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$124.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $232.92 2021-2023 Tezspire
Genzyme Corporation $125.00 2021
Janssen Pharmaceuticals, INC $120.66 2019
Genentech USA, INC. $99.99 2019
Inari Medical, INC. $96.44 2019
Glaxosmithkline, LLC. $77.39 2019
Philips North America LLC $27.27 2022
Allergan, INC. $13.74 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Armin Krvavac

$793.41

in general payments reported 2019-2025

Years
2019-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/188185/armin-krvavac

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.